Study Supports Sucampo's Amitiza in IBS
Posted on: Monday, 21 May 2007, 12:00 CDT
Sucampo Pharmaceuticals said that a new study has demonstrated that the active ingredient in Amitiza, given 8mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation.
Amitiza (lubiprostone) is marketed in the US for chronic idiopathic constipation, and the new study compared Amitiza with placebo in two groups of patients with irritable bowel syndrome with constipation (IBS-C).
"In this study, patients receiving lubiprostone were nearly twice as likely to achieve an overall response from symptoms of IBS-C compared to those receiving placebo," said Douglas Drossman, primary investigator, University of North Carolina.
IBS is a condition that affects approximately 58 million Americans and accounts for 25-50 percent of referrals to gastroenterologists. IBS-C symptoms include abdominal pain or discomfort associated with defecation or a change in bowel habits with features of disordered defecation.
Sucampo expects to submit a supplemental New Drug Application for IBS-C to the FDA by July 2007.
Source: Datamonitor
Related Articles
- Cleanliness is Next To
- Clinical Benefits Demonstrated With Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
- Pharmos Commences Phase 2b Irritable Bowel Syndrome Study; Trial to Evaluate Safety and Efficacy of Dextofisopam, a Novel First-in-Class Compound
- DEAR DR. GOTT: Thank You for Your Interesting, Useful...
- Daily Exercise Reduces Bowel Cancer Risk By 30 Pct
- Study Shows Digestive Drug Amitiza Provides Long-Term Relief
- Positive Phase Ib Trial for Alba's Celiac Disease Medicine
- Alba Therapeutics Announces Positive Phase Ib Clinical Trial Results
- Prolx Initiates Trial of Drug for Advanced Gastrointestinal Cancers
- ProlX Pharmaceuticals Corp. Initiates Phase 1B Trial in Gastrointestinal Cancer for Novel Thioredoxin Inhibitor PX-12
User Comments (0)
RSS Feeds